BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee I, Huang Y, Chau G, Huo T, Su C, Wu J, Lin H. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments: Interferon-gamma and HCC. Int J Cancer 2013. [DOI: 10.1002/ijc.28311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Takeba Y, Ohta Y, Ootaki M, Kobayashi T, Kida K, Watanabe M, Koizumi S, Otsubo T, Iiri T, Matsumoto N. Identification of interleukin-16 production on tumor aggravation in hepatocellular carcinoma by a proteomics approach. Tumour Biol 2021;43:309-25. [PMID: 34897107 DOI: 10.3233/TUB-211507] [Reference Citation Analysis]
2 Xu L, Ling J, Su C, Su YW, Xu Y, Jiang Z. Emerging Roles on Immunological Effect of Indoleamine 2,3-Dioxygenase in Liver Injuries. Front Med (Lausanne) 2021;8:756435. [PMID: 34869457 DOI: 10.3389/fmed.2021.756435] [Reference Citation Analysis]
3 He ZD, Zhang M, Wang YH, He Y, Wang HR, Chen BF, Tu B, Zhu SQ, Huang YZ. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. Acta Pharmacol Sin 2021;42:1516-23. [PMID: 33311600 DOI: 10.1038/s41401-020-00570-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
4 Kong R, Wang N, Han W, Bao W, Lu J. IFNγ-mediated repression of system xc- drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells. J Leukoc Biol 2021;110:301-14. [PMID: 34318944 DOI: 10.1002/JLB.3MA1220-815RRR] [Reference Citation Analysis]
5 Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:525-43. [PMID: 33850328 DOI: 10.1038/s41575-021-00438-0] [Cited by in Crossref: 127] [Cited by in F6Publishing: 103] [Article Influence: 127.0] [Reference Citation Analysis]
6 Balhorn R, Balhorn MC. Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers. Oncotarget 2020;11:3315-49. [PMID: 32934776 DOI: 10.18632/oncotarget.27709] [Reference Citation Analysis]
7 Morales J, Pawle RH, Akkilic N, Luo Y, Xavierselvan M, Albokhari R, Calderon IAC, Selfridge S, Minns R, Takiff L, Mallidi S, Clark HA. DNA-Based Photoacoustic Nanosensor for Interferon Gamma Detection. ACS Sens 2019;4:1313-22. [PMID: 30973005 DOI: 10.1021/acssensors.9b00209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
8 Li J, Yan K, Yang Y, Li H, Wang Z, Xu X. [Interleukin-17 promotes mouse hepatoma cell proliferation by antagonizing interferon-γ]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:1-5. [PMID: 30692059 DOI: 10.12122/j.issn.1673-4254.2019.01.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Liu Z, Poiret T, Meng Q, Rao M, von Landenberg A, Schoutrop E, Valentini D, Dodoo E, Peredo-Harvey I, Maeurer M. Epstein-Barr virus- and cytomegalovirus-specific immune response in patients with brain cancer. J Transl Med 2018;16:182. [PMID: 29970101 DOI: 10.1186/s12967-018-1557-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol 2018; 10(5): 108-114 [PMID: 29770170 DOI: 10.4251/wjgo.v10.i5.108] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
11 He X, Qu F, Zhou F, Zhou X, Chen Y, Guo X, Li J, Huang Q, Yang Y, Lyu Z, Zhang H, Xing J. High leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patients. Oncotarget 2016;7:22834-45. [PMID: 26985767 DOI: 10.18632/oncotarget.8071] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
12 Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS One 2017;12:e0188552. [PMID: 29176777 DOI: 10.1371/journal.pone.0188552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
14 Wu Q, Pi L, Le Trinh T, Zuo C, Xia M, Jiao Y, Hou Z, Jo S, Puszyk W, Pham K, Nelson DR, Robertson K, Ostrov D, Rameshwar P, Xia CQ, Liu C. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Mol Ther 2017;25:2299-308. [PMID: 28865999 DOI: 10.1016/j.ymthe.2017.08.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
15 Kalathil SG, Thanavala Y. High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy. Cancer Immunol Immunother. 2016;65:813-819. [PMID: 26910314 DOI: 10.1007/s00262-016-1810-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
16 Yan C, Huo X, Wang S, Feng Y, Gong Z. Stimulation of hepatocarcinogenesis by neutrophils upon induction of oncogenic kras expression in transgenic zebrafish. J Hepatol 2015;63:420-8. [PMID: 25828472 DOI: 10.1016/j.jhep.2015.03.024] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
17 Punt S, Langenhoff JM, Putter H, Fleuren GJ, Gorter A, Jordanova ES. The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology 2015;4:e984547. [PMID: 25949881 DOI: 10.4161/2162402X.2014.984547] [Cited by in Crossref: 64] [Cited by in F6Publishing: 38] [Article Influence: 9.1] [Reference Citation Analysis]
18 Zhou H, Wang L, Li X, Song J, Jiang T, Wu X, Zhou S. Interferon-γ +874A/T polymorphism and hepatocellular carcinoma risk: a meta-analysis. Med Sci Monit. 2015;21:689-693. [PMID: 25739411 DOI: 10.12659/msm.892885] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
19 Lin FC, Karwan M, Saleh B, Hodge DL, Chan T, Boelte KC, Keller JR, Young HA. IFN-γ causes aplastic anemia by altering hematopoietic stem/progenitor cell composition and disrupting lineage differentiation. Blood 2014;124:3699-708. [PMID: 25342713 DOI: 10.1182/blood-2014-01-549527] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]